365 related articles for article (PubMed ID: 33333686)
21. Genomic Landscape and Tumor Mutational Burden Determination of Circulating Tumor DNA in Over 5,000 Chinese Patients with Lung Cancer.
Shi J; Wang Z; Zhang J; Xu Y; Xiao X; Quan X; Bai Y; Yang X; Ming Z; Guo X; Feng H; Yang X; Zhuang X; Han F; Wang K; Shi Y; Lei Y; Bai J; Yang S
Clin Cancer Res; 2021 Nov; 27(22):6184-6196. PubMed ID: 34446541
[TBL] [Abstract][Full Text] [Related]
22. Genomic alterations of plasma cell-free DNAs in small cell lung cancer and their clinical relevance.
Du M; Thompson J; Fisher H; Zhang P; Huang CC; Wang L
Lung Cancer; 2018 Jun; 120():113-121. PubMed ID: 29748005
[TBL] [Abstract][Full Text] [Related]
23. Comprehensive Characterization of the Genomic Landscape in Chinese Pulmonary Neuroendocrine Tumors Reveals Prognostic and Therapeutic Markers (CSWOG-1901).
Peng W; Cao L; Chen L; Lin G; Zhu B; Hu X; Lin Y; Zhang S; Jiang M; Wang J; Li J; Li C; Shao L; Du H; Hou T; Chen Z; Xiang J; Pu X; Li J; Xu F; Loong H; Wu L
Oncologist; 2022 Mar; 27(2):e116-e125. PubMed ID: 35641209
[TBL] [Abstract][Full Text] [Related]
24. Identification and monitoring of somatic mutations in circulating cell-free tumor DNA in lung cancer patients.
Francaviglia I; Magliacane G; Lazzari C; Grassini G; Brunetto E; Dal Cin E; Girlando S; Medicina D; Smart CE; Bulotta A; Gregorc V; Pecciarini L; Doglioni C; Cangi MG
Lung Cancer; 2019 Aug; 134():225-232. PubMed ID: 31319985
[TBL] [Abstract][Full Text] [Related]
25. Small Cell Lung Cancer Exhibits Frequent Inactivating Mutations in the Histone Methyltransferase KMT2D/MLL2: CALGB 151111 (Alliance).
Augert A; Zhang Q; Bates B; Cui M; Wang X; Wildey G; Dowlati A; MacPherson D
J Thorac Oncol; 2017 Apr; 12(4):704-713. PubMed ID: 28007623
[TBL] [Abstract][Full Text] [Related]
26. Circulating mutational portrait of cancer: manifestation of aggressive clonal events in both early and late stages.
Yang M; Topaloglu U; Petty WJ; Pagni M; Foley KL; Grant SC; Robinson M; Bitting RL; Thomas A; Alistar AT; Desnoyers RJ; Goodman M; Albright C; Porosnicu M; Vatca M; Qasem SA; DeYoung B; Kytola V; Nykter M; Chen K; Levine EA; Staren ED; D'Agostino RB; Petro RM; Blackstock W; Powell BL; Abraham E; Pasche B; Zhang W
J Hematol Oncol; 2017 May; 10(1):100. PubMed ID: 28472989
[TBL] [Abstract][Full Text] [Related]
27. Repeatedly next-generation sequencing during treatment follow-up of patients with small cell lung cancer.
JiaXin Y; XiaoFeng C; PengFei C; Songchen Z; Ziling L
Medicine (Baltimore); 2023 Jun; 102(26):e34143. PubMed ID: 37390276
[TBL] [Abstract][Full Text] [Related]
28. Blood-based tumor mutational burden as a biomarker for atezolizumab in non-small cell lung cancer: the phase 2 B-F1RST trial.
Kim ES; Velcheti V; Mekhail T; Yun C; Shagan SM; Hu S; Chae YK; Leal TA; Dowell JE; Tsai ML; Dakhil CSR; Stella P; Jin Y; Shames DS; Schleifman E; Fabrizio DA; Phan S; Socinski MA
Nat Med; 2022 May; 28(5):939-945. PubMed ID: 35422531
[TBL] [Abstract][Full Text] [Related]
29. Genomic based analyses reveal unique mutational profiling and identify prognostic biomarker for overall survival in Chinese small-cell lung cancer.
Wang Y; Han X; Wang X; Sheng W; Chen Z; Shu W; Han J; Zhao S; Dai Y; Wang K; Shi W; Yang Z
Jpn J Clin Oncol; 2019 Dec; 49(12):1143-1150. PubMed ID: 31612912
[TBL] [Abstract][Full Text] [Related]
30. Targeted sequencing of plasma cell-free DNA to predict response to PD1 inhibitors in advanced non-small cell lung cancer.
Guibert N; Jones G; Beeler JF; Plagnol V; Morris C; Mourlanette J; Delaunay M; Keller L; Rouquette I; Favre G; Pradines A; Mazieres J
Lung Cancer; 2019 Nov; 137():1-6. PubMed ID: 31518912
[TBL] [Abstract][Full Text] [Related]
31. Circulating tumor DNA analysis depicts subclonal architecture and genomic evolution of small cell lung cancer.
Nong J; Gong Y; Guan Y; Yi X; Yi Y; Chang L; Yang L; Lv J; Guo Z; Jia H; Chu Y; Liu T; Chen M; Byers L; Roarty E; Lam VK; Papadimitrakopoulou VA; Wistuba I; Heymach JV; Glisson B; Liao Z; Lee JJ; Futreal PA; Zhang S; Xia X; Zhang J; Wang J
Nat Commun; 2018 Aug; 9(1):3114. PubMed ID: 30082701
[TBL] [Abstract][Full Text] [Related]
32. Genomic Profiling of Blood-Derived Circulating Tumor DNA from Patients with Advanced Biliary Tract Cancer.
Chen C; Wang T; Yang M; Song J; Huang M; Bai Y; Su H
Pathol Oncol Res; 2021; 27():1609879. PubMed ID: 34720757
[No Abstract] [Full Text] [Related]
33. Tumor Mutational Burden and Genomic Alterations in Chinese Small Cell Lung Cancer Measured by Whole-Exome Sequencing.
Su S; Zou JJ; Zeng YY; Cen WC; Zhou W; Liu Y; Su DH; Zhang XL; Huang HY; Lei A; Huang ZH; Jin Y; Li L; Su N; Xie YL; Zhao ZG; Liu JX
Biomed Res Int; 2019; 2019():6096350. PubMed ID: 31781628
[TBL] [Abstract][Full Text] [Related]
34. Circulating tumor DNA detection is correlated to histologic types in patients with early-stage non-small-cell lung cancer.
Zhang B; Niu X; Zhang Q; Wang C; Liu B; Yue D; Li C; Giaccone G; Li S; Gao L; Zhang H; Wang J; Yang H; Wu R; Ni P; Wang C; Ye M; Liu W
Lung Cancer; 2019 Aug; 134():108-116. PubMed ID: 31319968
[TBL] [Abstract][Full Text] [Related]
35. [Analysis of the feasibility and prognostic value of circulating tumor DNA monitoring in detecting gene mutations in patients with diffuse large B-cell lymphoma receiving chimeric antigen receptor T-cell therapy].
Zhou LH; Feng YQ; Hu YX; Huang H
Zhonghua Xue Ye Xue Za Zhi; 2023 Oct; 44(10):805-812. PubMed ID: 38049331
[No Abstract] [Full Text] [Related]
36. [Detection of circulating tumor DNA in epidermal growth factor receptor-TKI relapsed non-small cell lung cancer patients using next-generation sequencing and an analysis of the resistant mechanisms].
Li Y; Zhang FS; Guo L; Ying JM
Zhonghua Bing Li Xue Za Zhi; 2018 Dec; 47(12):904-909. PubMed ID: 30522169
[No Abstract] [Full Text] [Related]
37. Base-Position Error Rate Analysis of Next-Generation Sequencing Applied to Circulating Tumor DNA in Non-Small Cell Lung Cancer: A Prospective Study.
Pécuchet N; Zonta E; Didelot A; Combe P; Thibault C; Gibault L; Lours C; Rozenholc Y; Taly V; Laurent-Puig P; Blons H; Fabre E
PLoS Med; 2016 Dec; 13(12):e1002199. PubMed ID: 28027313
[TBL] [Abstract][Full Text] [Related]
38. The Prognostic Value of ctDNA and bTMB on Immune Checkpoint Inhibitors in Human Cancer.
Wei J; Feng J; Weng Y; Xu Z; Jin Y; Wang P; Cui X; Ruan P; Luo R; Li N; Peng M
Front Oncol; 2021; 11():706910. PubMed ID: 34660274
[TBL] [Abstract][Full Text] [Related]
39. Changes in the gene mutation profiles of circulating tumor DNA detected using CAPP-Seq in neoadjuvant chemotherapy-treated advanced ovarian cancer.
Noguchi T; Sakai K; Iwahashi N; Matsuda K; Matsukawa H; Yahata T; Toujima S; Nishio K; Ino K
Oncol Lett; 2020 Apr; 19(4):2713-2720. PubMed ID: 32218822
[TBL] [Abstract][Full Text] [Related]
40. An exploration of LAF-bTMB as a predictor for the efficacy of immunotherapy combined with chemotherapy in non-small cell lung cancer.
Zhang S; Yang L; Yang Y; Xin Y; Wang Y
Thorac Cancer; 2022 Dec; 13(23):3374-3383. PubMed ID: 36274215
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]